Tech Company Financing Transactions
ONL Therapeutics Funding Round
On 12/28/2020, ONL Therapeutics secured $46.9 million in Series B funding from Bios Partners, Biosciences Research and Commercialization Center and Capital Community Angels Investors.
Transaction Overview
Company Name
Announced On
12/28/2020
Transaction Type
Venture Equity
Amount
$46,900,000
Round
Series B
Investors
Proceeds Purpose
This funding supports the completion of a Phase 1 study in retinal detachment with ONL's lead compound ONL1204.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
PO Box 131547
Ann Arbor, MI 48113
USA
Ann Arbor, MI 48113
USA
Phone
Website
Email Address
Overview
ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Esposito
Chief Scientific Officer
David Zacks
VP - Bus. Development
Jana Goor
VP - R & D
Andrew Kocab
Browse more venture capital transactions:
Prev: 12/25/2020: PanDX venture capital transaction
Next: 12/28/2020: Cedar Gate venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs